Published in Ocular Surface

The Role of Tear Film Biomarkers in Diagnosing and Managing DED

This is editorially independent content
4 min read

Sit down with Drs. Damon Dierker and Jerry Robben to review how to interpret and integrate tear film biomarkers into dry eye disease management workflows.

Damon Dierker, OD, FAAO, Director of Clinical Strategy & Optometric Services at Eye Surgeons of Indiana, hosted Jerry Robben, OD, chief optometrist and director of clinical research at Bowden Eye and Associates in Jacksonville, Florida, and adjunct clinical assistant professor at the Arizona College of Optometry, for a Dry Eye Fireside Chat on tear film biomarkers.
More than a decade ago, Dr. Robben’s first matrix metalloproteinase 9 (MMP-9) test contradicted his slit lamp exam. Today, his team runs osmolarity and MMP-9 on every suspected dry eye patient before the doctor walks in. Osmolarity anchors the diagnosis and the follow-up, and MMP-9 exposes inflammation that a quiet-looking eye can hide.

“With the first patient, I was dead wrong. I wouldn’t have added an immunomodulator or a steroid. The symptoms weren’t off the charts, but the MMP-9 was positive. And it completely changed what I was going to do for that patient that day; we did add an immunomodulator.”

Tear film biomarkers in DED fast facts

  • Start with a questionnaire: A SPEED (Standardized Patient Evaluation of Eye Dryness) score of 1 or higher 
  • Monitor results: If you can run only one point-of-care test, run osmolarity, and repeat it at follow-up to track trends.
  • DEWS III diagnosis: Per the Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) III, symptoms plus one of: noninvasive tear breakup time (NITBUT) under 10 seconds; osmolarity ≥308 mOsm/L or an interocular difference above 8 mOsm/L; or ocular surface staining1
  • MMP-9 (in trial): 85% sensitivity and 94% specificity2
  • MMP-9 (in practice): 70% to 81% sensitivity and 38% specificity3
  • Interpreting findings: Let abnormal results point to the cause. A hyperosmolar, inflamed eye often needs MGD addressed, not just another drop.

What MMP-9 catches, and what it misses

Dr. Robben had assumed he could spot inflammation at the slit lamp. The patient’s symptoms were modest, yet the strip came back positive, so he started a loteprednol etabonate (Lotemax) pulse. A positive strip means tear MMP-9 is at or above 40 ng/mL,3 which Dr. Robben reads as a sign that epithelial cells are being damaged.
The original trial reported 85% sensitivity and 94% specificity across 143 patients with dry eye and 63 healthy controls.2 A 2025 analysis of 1,515 patients at a Bogotá dry eye clinic found 81% sensitivity against the trial’s criteria.3
Those criteria required an Ocular Surface Disease Index (OSDI) score of 13 or higher, Schirmer under 10 mm, breakup time under 10 seconds, and staining all at once. Against the broader TFOS DEWS II criteria, sensitivity fell to 70%, with 38% specificity under both. The authors cautioned that the test should not be used on its own to diagnose dry eye, because it misses milder disease.3

Osmolarity as the intraocular pressure of dry eye

Under TFOS DEWS III, a positive symptom screen plus any one abnormal sign confirms dry eye: NITBUT under 10 seconds, osmolarity of 308 mOsm/L or higher in either eye (or an interocular difference above 8 mOsm/L), or ocular surface staining.1 MMP-9 is not one of the criteria.

“For me osmolarity is kind of like IOP in glaucoma. We check it once a patient’s established they have dry eye, we check it every time they come in. We’re looking for trends.”

As Dr. Dierker notes, osmolarity tells you there is a problem but not why. A high reading means the tear film is too concentrated, either because too little aqueous is produced or because too much evaporates, and Dr. Robben says the likeliest culprit is meibomian gland dysfunction (MGD). For Dr. Dierker, a symptomatic MGD patient with a positive MMP-9 is often a fast track to an intense pulsed light (IPL) discussion.

“When you have MGD, you have blocked glands and until you address that, you’re just ignoring the problem and pacifying it.”

Building the workflow

At Bowden Eye and Associates, a SPEED score of 1 or higher sends technicians to run osmolarity, MMP-9, meibography, and a lipid layer or dynamic breakup measurement as standing orders. Osmolarity repeats at nearly every visit; MMP-9 repeats at complete exams, with new symptoms, or to confirm treatment worked.
Dr. Robben uses the questionnaire as evidence—a patient may report feeling “about the same” at 6 weeks while their SPEED score has dropped from 8 to 2, and that number changes the conversation.
Watch the full conversation to hear how Drs. Dierker and Robben build osmolarity and MMP-9 testing into daily practice. For more on the workup, read How to Identify DED in a Comprehensive Eye Exam.

This article was written by Keren Beki based on the recorded conversation between Drs. Dierker and Robben.

Want this episode in podcast form? Subscribe to Dry Eye Fireside Chat on your favorite podcasting platforms!

  1. Wolffsohn JS, Benítez-Del-Castillo JM, Loya-Garcia D, et al. TFOS DEWS III: diagnostic methodology. Am J Ophthalmol. 2025;279:387-450. doi:10.1016/j.ajo.2025.05.033
  2. Sambursky R, Davitt WF III, Latkany R, et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol. 2013;131(1):24-28. doi:10.1001/jamaophthalmol.2013.561
  3. Mejía-Salgado G, Rojas-Carabali W, Cifuentes-González C, et al. Real-world performance of the InflammaDry test in dry eye diagnosis: an analysis of 1,515 patients. Graefes Arch Clin Exp Ophthalmol. 2025;263(6):1623-1631. doi:10.1007/s00417-025-06760-6
Damon Dierker, OD, FAAO
About Damon Dierker, OD, FAAO

Dr. Dierker is Director of Clinical Strategy & Optometric Services at Eye Surgeons of Indiana, an adjunct faculty member at the Indiana University School of Optometry, and Immediate Past President of the Indiana Optometric Association. Dr. Dierker is the Co-Founder and Program Chair of Eyes On Dry Eye, the largest event for eyecare professionals in the industry. He has made significant contributions to raising awareness of dry eye and ocular surface disease in the eyecare community, including the development of Dry Eye Boot Camp and other content resources across dozens of publications.

Damon Dierker, OD, FAAO
Jerry Robben, OD
About Jerry Robben, OD

Dr. Jerry Robben attended Kansas State University where he was active in a research laboratory group doing work on cataract prevention and other eye research. He graduated from Kansas State University with a Bachelor of Science degree in biochemistry.

He then used his background in ocular research to attend and graduate from Nova Southeastern University, College of Optometry in Fort Lauderdale, Florida, where he received a second Bachelor's Degree in Vision Science and his Doctorate of Optometry.

Dr. Robben is now a senior member of the provider team and is the Chief Optometrist at Bowden Eye & Associates. Additionally, he is an Adjunct Clinical Assistant Professor for the Arizona College of Optometry and the Chicago College of Optometry, where he continues to supervise Optometry Resident Doctors who are currently completing their externships at our clinical sites for graduation from these institutions.

He is also the Director of Clinical Research at Bowden Eye & Associates and heads the team in multiple clinical studies that are investigating new treatments and diagnostics in the fields of glaucoma, dry eye disease, conjunctivitis, neurotrophic corneal disease, presbyopia, surgical interventions, and other ocular diseases.

Jerry Robben, OD
💙 Dry Eye Fireside Chat
Bausch + Lomb Blink